Newborn Screening Market
There are nearly 130 million babies born in the world each year. Mostly the babies are born healthy whereas some infants show serious and potentially fatal medical conditions which can have the long-term effects on a child’s health. Medical professionals use the newborn screening tests to diagnose and treat such conditions. There are three major newborn screening tests, blood test (heel stick); the hearing screen; and pulse oximetry. Also, there are few more screening tests which can be performed on newborn family’s requirements; phenylketonuria (PKU), congenital hypothyroidism, galactosemia, sickle cell disease, biotinidase deficiency, congenital adrenal hyperplasia (CAH), maple syrup urine disease (MSUD), tyrosinemia, cystic fibrosis (CF), MCAD deficiency, severe combined immunodeficiency (SCID), critical congenital heart defects (CCHD) and toxoplasmosis.
Rising incidence of neonatal diseases, increasing demand for newborn diagnosis, growing Government initiatives to create awareness about neonatal hereditary diseases and increase in funding from Government and private organizations in the developing countries are driving the newborn or neonatal screening market. Sponsoring various awareness programs and conferences by private companies on neonatal care across the globe is likely to drive the newborn screening market. However, factors such as lack of trained professionals, lack of healthcare infrastructure, the stringent regulatory scenario in few countries, unavailability of advanced instruments in developing countries and lack of awareness are restricting the growth of the newborn screening market.
The global newborn screening market is segmented on the basis of test type, products, technology, and geography.On the basis of test type, the newborn screening market is divided into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test. By technology, the newborn screening market is classified into Tandem Mass Spectrometry (TMS) electrophoresis, Immunoassays & Enzymatic assays, Hearing Screen Technology, DNA-based assays, and Pulse Oximetry Screening Technology. On the basis of products, the newborn screening market is bifurcated into instruments and reagents and assay kits. The Instruments are sub-divided into newborn disorder screening instruments, newborn hearing screening instruments, and pulse oximeters instruments.
In terms of regional analysis, North America is leading the global newborn screening market, owing to rising Government initiatives to promote neonatal screening, growing research activities in the early diagnosis and treatment of rare neonatal diseases, the introduction of new test methods, and rising demand for advanced and quick screening tests.Asia Pacific is expected to grow at the highest CAGR owing to the rising incidence of premature babies and increased investment by private players in the healthcare infrastructure.
Major players in the global newborn screening market are Bio-Rad Laboratories (U.S.), AB SCIEX (U.S.), Covidien PLC (Ireland), PerkinElmer Inc. (U.S.), GE Life Sciences (U.K.), Agilent Technologies (U.S.), Waters Corporation (U.S.), Thermo Fisher Scientific Inc., Natus Medical Inc. (U.S.), Masimo Corporation (U.S.), Medtronic, and Trivitron Healthcare (India) among others.